by Anne-Claire Hardy-Bessard, Fabien Brocard, Florian
Clatot, Alain Lortholary, Benoît You, Julien Grenier, Jérôme Martin-Babau,
Brigitte Lucas, Jérôme Meunier, Jean-Marc Ferrero, Aude-Marie Savoye, Adina
Marti, Raymond Despax, Isabelle Moullet, George Emile
The Breast: Open
Access: Published: September 30, 2020
Combining bevacizumab with paclitaxel significantly improves
progression-free survival (PFS) versus paclitaxel alone in HER2-negative
metastatic breast cancer (MBC). Eribulin is active and tolerable in pretreated
MBC. To assess whether eribulin may offer a more tolerable yet effective
combination partner for bevacizumab, we evaluated a bevacizumab/eribulin
combination regimen as first-line therapy for MBC.
